{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:04:36Z","timestamp":1784178276105,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optimizing tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) requires careful consideration of patient quality of life (QoL), which significantly influences treatment adherence and long-term outcomes. Long-term treatment can be associated with persistent symptoms that may negatively impact QoL, adherence, and patient satisfaction. This nationwide Italian survey explored patient experiences, treatment patterns, and factors influencing clinical decision-making in CML, with the aim of better understanding unmet needs and potential barriers to optimal care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional survey involving 146 adult patients with CML. A structured questionnaire, developed collaboratively by hematologists and patient association representatives, assessed patient-reported outcomes (PROs), treatment-related burden, and care satisfaction. Analyses were descriptive and exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite the availability of effective therapies, a substantial proportion of patients reported impaired QoL due to both disease and treatment-related factors. While most patients reported overall satisfactory QoL, 26% described low or very low QoL. The burden was particularly evident in specific patient subgroups and in later lines of therapy, reflecting a significant physical and psychological impact of CML and its management. Fatigue, weakness, and muscle pain were the most frequently reported symptoms, often persistent and affecting daily functioning. Female patients reported a higher symptom burden and greater psychological distress compared to males. Despite high overall satisfaction with healthcare professionals, relevant unmet needs were identified, particularly regarding information on supportive services, long-term disease management, and fertility-related issues. Treatment-related adverse events were common and frequently chronic, suggesting a substantial cumulative burden over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the effectiveness of TKIs, patients with CML continue to experience a meaningful and multidimensional burden, particularly in later treatment lines and specific subgroups. These findings highlight the importance of greater attention to patient-centered management in CML, with treatment decisions carefully balancing the benefits and limitations of available therapeutic options to optimize both clinical outcomes and quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1846801","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:21:06Z","timestamp":1784175666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Unmet needs and quality of life burden in chronic myeloid leukemia: results from a nationwide Italian real-world survey"],"prefix":"10.3389","volume":"16","author":[{"given":"Elisabetta","family":"Abruzzese","sequence":"first","affiliation":[{"name":"Department of Hematology, S Eugenio Hospital, Tor Vergata University, ASL Roma2","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera Rilievo Nazionale (AORN) Cardarelli","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Bombaci","sequence":"additional","affiliation":[{"name":"AIL- Associazione Italiana Contro Leucemie, Linfomi, Mieloma","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Russo Rossi","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Galante","sequence":"additional","affiliation":[{"name":"Bianco Airone A.P.S.","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Misto","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A","place":["Milano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Valsecchi","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A","place":["Milano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniia","family":"Gushchina","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A","place":["Milano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejme2407913","article-title":"CML 25 years later \u2014 poised for another breakthrough","volume":"391","author":"Abruzzese","year":"2024","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2018.11.005","article-title":"What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials","volume":"41","author":"Bosi","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02159-0","article-title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","volume":"38","author":"Jabbour","year":"2024","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016042","article-title":"Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL","volume":"9","author":"Mauro","year":"2025","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad119","article-title":"The EMA assessment of asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with at least two tyrosine kinase inhibitors","volume":"28","author":"Tesileanu","year":"2023","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70000","article-title":"Treatment\u2010free remission in chronic myeloid leukemia: Revisiting the \u201cW\u201d questions","volume":"115","author":"Bruzzese","year":"2025","journal-title":"Eur J Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12672-024-01444-9","article-title":"Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta-analysis","volume":"15","author":"Zheng","year":"2024","journal-title":"Discover Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.04.005","article-title":"Considerations for treatment-free remission in patients with chronic myeloid leukemia: A joint patient\u2013physician perspective","volume":"18","author":"Saglio","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18101656","article-title":"Assessment of transitioning from high-potency to low-potency inhibitors in chronic myeloid leukemia (CML) patients: The Downgrading-Impact (D-IMPACT) project","volume":"18","author":"Abruzzese","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287772","article-title":"Improving chronic myeloid leukemia management and quality of life: Patient and physician survey on unmet needs from the CML SUN survey","author":"Lang","year":"","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00520-025-09451-4","article-title":"Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: A systematic review and meta-analysis","volume":"33","author":"Smit","year":"2025","journal-title":"Supportive Care Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35021","article-title":"Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia","volume":"130","author":"Efficace","year":"2024","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3295-8","article-title":"Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: The DASPERSE study","volume":"97","author":"Kim","year":"2018","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: Analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood.v112.11.1099.1099","article-title":"Imatinib Long Term Effects (ILTE) Study: An independent, international study in CML patients","volume":"112","author":"Gambacorti-Passerini","year":"2008","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1182\/blood-2018-99-116916","article-title":"Treatment decision making and treatment satisfaction among individuals living with chronic myeloid leukemia","volume":"132","author":"Olson","year":"2018","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0306-5","article-title":"Quality of life and long-term therapy in patients with chronic myeloid leukemia","volume":"11","author":"Flynn","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-023-00703-w","article-title":"Real-world management of CML: Outcomes and treatment patterns","volume":"18","author":"Held","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133597","article-title":"Real-world analysis of the therapeutic management and disease burden in chronic myeloid leukemia patients with later lines in Italy","volume":"11","author":"Breccia","year":"2022","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58986","article-title":"Treatment adherence and quality of life among elderly patients with diabetes mellitus registered in the community","author":"Vafopoulou","year":"","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100692","article-title":"Illness and prognostic understanding in patients with hematologic Malignancies","volume":"45","author":"Gray","year":"2021","journal-title":"Blood Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4124-2","article-title":"Sexual health in patients with hematological Malignancies: A neglected issue","volume":"26","author":"Niscola","year":"2018","journal-title":"Supportive Care Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026513","article-title":"How I manage chronic myeloid leukemia during pregnancy","volume":"147","author":"Abruzzese","year":"2026","journal-title":"Blood J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02183-0","article-title":"Chronic myeloid leukemia diagnosed in pregnancy: Management and outcome of 87 patients reported to the European LeukemiaNet international registry","volume":"38","author":"Chelysheva","year":"2024","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: Opinion, evidence, and recommendations","volume":"11","author":"Abruzzese","year":"","journal-title":"Ther Adv Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:21:07Z","timestamp":1784175667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1846801"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1846801","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1846801"}}